Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Pegylated Liposomal Doxorubicin: A Guide To Its Use In Various Malignancies
K. Lyseng-Williamson, S. Duggan, G. Keating
Published 2013 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Pegylated liposomal doxorubicin (Caelyx® [EU], Doxil® [USA]) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile. As shown by evidence from clinical trials, intravenous pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma. It has a favourable safety profile relative to conventional doxorubicin and other available chemotherapy agents.
This paper references
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
D. Rayson (2012)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxanerefractory advanced breast cancer
Am Keller (2004)
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
J. Sehouli (2006)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
G. Ferrandina (2008)
Pegylated Liposomal Doxorubicin
S. Duggan (2012)
Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma
St Duggan (2011)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
D. Mutch (2007)
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
É. Pujade-Lauraine (2010)
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies
J. Kesterson (2010)
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
B. Monk (2012)
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma
Mary Cianfrocca (2010)
A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study.
E. Jäger (2010)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
R. Orlowski (2007)
Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study
J. Sehouli (2008)
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
B. Monk (2010)
Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first line chemotherapy for metastatic breast cancer (MBC) – The PELICAN study
S. Al-Batran (2008)
Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma
L. Martín-Carbonero (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer
Y. Yıldırım (2007)
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
E. Alba (2010)
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies doxorubicin for first-line treatment of metastatic breast cancer
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
This paper is referenced by
Improvement of Cancer Therapy by Nanotechnology
C. Mohanty (2017)
Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy
D. Maples (2015)
Silicon-containing nanocarriers for targeted drug delivery: synthesis, physicochemical properties and acute toxicity
D. Sonin (2016)
The preclinical development of novel treatment options for advanced prostate cancer
Jan Kroon (2016)
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis
D. Lorusso (2019)
Comparison of therapeutic efficacy of lipo-doxorubicin and doxorubicin in treating bladder cancer
D. Yu (2017)
Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
J. Gong (2018)
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Jan Kroon (2015)
Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells
Shao-ling Wu (2014)
Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
S. Kusumoto (2015)
Milk derived colloid as a novel drug delivery carrier for breast cancer
M. Hayashi (2015)
Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients
T. Golan (2015)
Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study.
M. Camus (2019)
Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
Jo-Fan Chang (2019)
Delivery of Cancer Nanotherapeutics
Bomy Lee Chung (2019)
Nanomedicines for renal disease: current status and future applications
Nazila Kamaly (2016)
Clinical Translation of Nanomedicine.
Y. Min (2015)
Malignant cardiac tumors: diagnosis and treatment.
C. Lestuzzi (2015)
Liposome-encapsulated chemotherapy: Current evidence for its use in companion animals.
B. Børresen (2018)
Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Daniel C Pan (2020)